Health and Fitness Health and Fitness
Wed, March 7, 2012
[ Wed, Mar 07th 2012 ] - Market Wire
CytoSorbents to Exhibit and Host Research Symposi .. m at Major International Critical Care Conference
[ Wed, Mar 07th 2012 ] - Market Wire
SPX-106T Arrests Development of Atherosclerotic Plaques in Mouse Model of Cardiovascular Disease
[ Wed, Mar 07th 2012 ] - Market Wire
Fourteenth Patient Dosed in Neuralstem ALS Stem Cell Trial
[ Wed, Mar 07th 2012 ] - Market Wire
Prana Doses First Patient in the "IMAGINE" Phase II Alzheimer's Disease Trial
[ Wed, Mar 07th 2012 ] - Market Wire
GenVec to Release Fourth Quarter and Year-End 201 .. s and Conduct a Conference Call on March 15, 2012
[ Wed, Mar 07th 2012 ] - Market Wire
Immunovaccine Raises CAN$2.8M in Non-Brokered Private Placement
[ Wed, Mar 07th 2012 ] - Market Wire
Boehringer Ingelheim and Lilly's new oral type 2 .. , Jentaduetoa" (linagliptin/metformin hydrochlori
[ Wed, Mar 07th 2012 ] - Market Wire
EnteroMedics to Present at the 24th Annual ROTH Capital Growth Conference
[ Wed, Mar 07th 2012 ] - Market Wire
Isis Initiates Phase 1 Study in Patients With Can .. First Generation 2.5 Antisense Drug, ISIS-STAT3Rx
[ Wed, Mar 07th 2012 ] - Market Wire
Discovery Labs to Hold Conference Call to Discuss FDA Approval of SURFAXIN (lucinactant)
[ Wed, Mar 07th 2012 ] - Market Wire
Transcept Pharmaceuticals to Report Fourth Quarte .. l Results and Host Conference Call on March 14, 2
[ Wed, Mar 07th 2012 ] - Market Wire
Synthetic Biologics to Present at ROTH Annual Growth Stock Conference
[ Wed, Mar 07th 2012 ] - Market Wire
Palatin Technologies, Inc. to Present at the 24th Annual ROTH OC Growth Stock Conference
[ Wed, Mar 07th 2012 ] - Market Wire
iBio to Present at the 24th Annual ROTH Conference on March 14
[ Wed, Mar 07th 2012 ] - Market Wire
CMS Assigns Payment to Novadaq's SPY Imaging Under OPPS
[ Wed, Mar 07th 2012 ] - Market Wire
Horizon Pharma Enters Into Exclusive Agreement Wi .. ization of LODOTRA(R) (Modified-Release Prednison
[ Wed, Mar 07th 2012 ] - Market Wire
Prominent Harvard Cardiologist Joins VentriPoint Scientific Advisory Board
[ Wed, Mar 07th 2012 ] - Market Wire
MELA Sciences Announces Commercial Launch of MelaFind(R)
[ Wed, Mar 07th 2012 ] - Market Wire
Solta Medical Provides Update on Liposonix Launch
[ Wed, Mar 07th 2012 ] - Market Wire
The Ensign Group Acquires an Idaho Skilled Nursing Facility
[ Wed, Mar 07th 2012 ] - Market Wire
OncoSec's OMS ElectroImmunotherapy Technology Pla .. I Merkel Cell Carcinoma Clinical Trial Featured i
[ Wed, Mar 07th 2012 ] - Market Wire
Inovio Appoints Vaccine Industry Leader to its Scientific Advisory Board
Tue, March 6, 2012
[ Tue, Mar 06th 2012 ] - Market Wire
AcelRx Announces Initiation of Phase 3 Clinical P .. anil NanoTab PCA System for the Treatment of Post
[ Tue, Mar 06th 2012 ] - Market Wire
Columbia Laboratories Receives Nasdaq Minimum Bid Price Non-compliance Letter
[ Tue, Mar 06th 2012 ] - Market Wire
China Pharma Holdings, Inc. to Report Fiscal Year 2011 Financial Results on March 15, 2012
[ Tue, Mar 06th 2012 ] - Market Wire
Nordion Reports First Quarter 2012 Financial Results
[ Tue, Mar 06th 2012 ] - Market Wire
Discovery Labs Announces FDA Approval of SURFAXIN .. ) for Prevention of Respiratory Distress Syndrome
[ Tue, Mar 06th 2012 ] - Market Wire
Centene Corporation to Present at Barclays Capital 2012 Global Healthcare Conference
[ Tue, Mar 06th 2012 ] - Market Wire
HeartWare Presentation At The Barclays Capital 2012 Global Healthcare Conference To Be Webcast
[ Tue, Mar 06th 2012 ] - Market Wire
SciClone Pharmaceuticals to Report Financial Resu .. d Year Ended 2011 and Outlook for 2012 on March 1

SciClone Pharmaceuticals to Report Financial Results for the Fourth Quarter and Year Ended 2011 and Outlook for 2012 on March 1


Published on 2012-03-06 13:06:08 - Market Wire
  Print publication without navigation


March 06, 2012 16:00 ET

SciClone Pharmaceuticals to Report Financial Results for the Fourth Quarter and Year Ended 2011 and Outlook for 2012 on March 13

FOSTER CITY, CA--(Marketwire - Mar 6, 2012) - SciClone Pharmaceuticals, Inc. (NASDAQ: [ SCLN ]) today announced that it plans to report fourth quarter and full year 2011 financial results on Tuesday, March 13, 2012. SciClone will host a conference call and webcast to provide a business and product update at 4:30 pm ET that day. The call will be hosted by Friedhelm Blobel, Ph.D., President and CEO, and Gary Titus, Senior Vice President and CFO.

LIVE CALL:
866-730-5769 (U.S./Canada)
857-350-1593 (International)
Passcode: 99060403
REPLAY:
888-286-8010 (U.S./Canada)
617-801-6888 (International)
Passcode: 14328384
(Replay available from Tuesday, March 13, 2012, at 6:30 pm ET until 11:59 pm ET on Tuesday, March 20, 2012)

The conference call will contain forward-looking statements. Interested parties who wish to listen to the webcast should visit the Investor Relations section of SciClone's website at [ www.sciclone.com ]. The information provided on the teleconference is accurate only at the time of the conference call, and SciClone will take no responsibility for providing updated information except as required by law.

About SciClone
SciClone Pharmaceuticals is a revenue-generating, profitable, specialty pharmaceutical company with a substantial commercial business in China and a product portfolio of therapies for oncology, infectious diseases and cardiovascular, urological, respiratory, and central nervous system disorders. SciClone's ZADAXIN® (thymalfasin) is approved in over 30 countries and may be used for the treatment of hepatitis B (HBV), hepatitis C (HCV), as a vaccine adjuvant, and certain cancers according to the local regulatory approvals. Besides ZADAXIN, SciClone markets about 15 mostly partnered products in China, including Depakine®, the most widely prescribed broad-spectrum anti-convulsant in China; Tritace®, an ACE inhibitor for the treatment of hypertension; Stilnox®, a fast-acting hypnotic for the short-term treatment of insomnia (marketed as Ambien® in the US); and Aggrastat®, a recently-launched interventional cardiology product. SciClone is also pursuing the registration of several other therapeutic products in China. SciClone is headquartered in Foster City, California. For additional information, please visit [ www.sciclone.com ].

Ambien, Depakine, Stilnox and Tritace are registered trademarks of Sanofi.

Aggrastat is a registered trademark of Merck & Co., Inc.


Contributing Sources